摘要
目的探讨宣肺败毒方治疗新型冠状病毒感染的中医学理论,归纳该方的药理实验研究进展,为扩展该方的临床应用和进一步的实验研究提供参考。方法采用理论研究与文献调研相结合的方法,探讨宣肺败毒方的中医学理论和药理学进展,归纳该方的实验研究。结果宣肺败毒方适用于湿毒郁肺的患者,宣肺败毒方可通过PD-1/IL17A、IL-6/STAT3及CXCL2/CXCR2等通路改善肺损伤,以及NF-κB通路减轻肠道疾病。结论宣肺败毒方是中药和科技结合的产物,既有充分的中医药理论支撑,亦有足够的现代药理实验研究证据支持。
Objective To discuss the traditional Chinese medicine(TCM)theory of Xuanfei Baidu decoction in treating novel coronavirus infection,summarize the experimental study of this prescription,and provide reference for later clinical and experimental purposes.Methods Using the methods of theoretical research and literature investigation,this paper discusses and summarizes the TCM theory of Xuanfei Baidu decoction and summarizes the experimental study.Results Xuanfei Baidu decoction is suitable for patients with dampness-toxic stagnation of lung.And the PD-1/IL17A,IL-6/STAT3 and CXCL2/CXCR2 pathways were used to ameliorate lung injury and NF-κB pathway to alleviate intestinal diseases.Conclusion Xuanfei Baidu decoction is a combination of TCM and science and technology,which is supported by both TCM theory and modern experimental research evidence.
作者
张敬升
冀祖恩
庞博
徐英莉
曹姗
张宇
孙绮悦
孙静
李舒冉
张薇
赵荣华
崔晓兰
ZHANG Jingsheng;JI Zuen;PANG Bo;XU Yingli;CAO Shan;ZHANG Yu;SUN Qiyue;SUN Jing;LI Shuran;ZHANG Wei;ZHAO Ronghua;CUI Xiaolan(Institute of Chinese Materia Medica,China Academy of Chinese MedicalSciences,Beijing 100700,China;Xinjiang Key Laboratory for Research of Licorice and Products,Korla Xinjiang 841011,China;Xinjiang Quanan Pharmaceutical Co.,Ltd.,Korla Xinjiang 841011,China)
出处
《中国药物警戒》
2024年第1期55-58,64,共5页
Chinese Journal of Pharmacovigilance
基金
国家重点研发计划(2021YFC1712903)
中国中医科学院科技创新工程(C12021A04606)。
关键词
宣肺败毒方
新型冠状病毒感染
湿毒郁肺
中医学
药理
Xuanfei Baidu decoction
Coronavirus Disease 2019(COVID-19)
lung with dampness-toxic stagnation
traditional Chinese medicine
pharmacology
